Literature DB >> 4180995

Metabolism of 35S-labelled antithyroid drugs in man.

W D Alexander, V Evans, A MacAulay, T F Gallagher, J Londono.   

Abstract

Differences in the metabolic fate of antithyroid drugs influence the optimal frequency of administration and their therapeutic efficacy. (35)S propylthiouracil differed from the (35)S imidazoles (carbimazole and methimazole) in the more rapid absorption and excretion and the shorter biological half-life in the plasma of the former. Renal function may have a more important influence on the biological half-life of the drugs than thyroid status. Further work is required to determine the optimal frequency of administration for each compound.

Entities:  

Mesh：

Substances：

Year:  1969        PMID： 4180995      PMCID： PMC1983143          DOI： 10.1136/bmj.2.5652.290

Source DB:  PubMed          Journal:  Br Med J        ISSN： 0007-1447


  3 in total

1.  The desulfuration of thiourea by thyroid cytoplasmic particulate fractions.

Authors:  F MALOOF; L SPECTOR
Journal:  J Biol Chem       Date:  1959-04       Impact factor: 5.157

2.  Studies on the metabolism of thiourea. II. The metabolic fate of thiourea in the thyroid gland.

Authors:  J SCHULMAN
Journal:  J Biol Chem       Date:  1950-10       Impact factor: 5.157

3.  Development of thyroidal suppression by triiodothyronine during six months' treatment of thyrotoxicosis with antithyroid drugs.

Authors:  W D Alexander; R M Harden; J Shimmins; D McLarty; P McGill
Journal:  J Clin Endocrinol Metab       Date:  1967-12       Impact factor: 5.958
  3 in total
  9 in total

Review 1.  Thyroid disorders--management.

Authors:  R N Smith
Journal:  Br Med J       Date:  1970-03-21

Review 2.  Influence of thyroid dysfunction on drug pharmacokinetics.

Authors:  G M Shenfield
Journal:  Clin Pharmacokinet       Date:  1981 Jul-Aug       Impact factor: 6.447

Review 3.  Pharmacokinetics of antithyroid drugs.

Authors:  G Benker; D Reinwein
Journal:  Klin Wochenschr       Date:  1982-06-01

4.  Pharmacokinetic properties and bioavailability of methimazole.

Authors:  R Jansson; B Lindström; P A Dahlberg
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

5.  Initial treatment of thyrotoxic Graves' disease with methimazole: a randomized trial comparing different dosages.

Authors:  M Messina; P Milani; L Gentile; A Monaco; C Brossa; M Porta; F Camanni
Journal:  J Endocrinol Invest       Date:  1987-06       Impact factor: 4.256

Review 6.  Clinical pharmacokinetics of antithyroid drugs.

Authors:  J P Kampmann; J M Hansen
Journal:  Clin Pharmacokinet       Date:  1981 Nov-Dec       Impact factor: 6.447

7.  Potential radiopharmaceuticals for the detection of ocular melanoma. Part I. 5-iodo-2-thiouracil derivatives.

Authors:  A van Langevelde; C N Bakker; H J Broxterman; J G Journée-de Korver; F M Kaspersen; J A Oosterhuis; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1983

8.  The pharmacokinetics of methimazole after oral administration of carbimazole and methimazole, in hyperthyroid patients.

Authors:  G G Skellern; B I Knight; C K Low; W D Alexander; D G McLarty; W J Kalk
Journal:  Br J Clin Pharmacol       Date:  1980-02       Impact factor: 4.335

9.  Methimazole as a protectant against cisplatin-induced nephrotoxicity using the dog as a model.

Authors:  D M Vail; A A Elfarra; A J Cooley; D L Panciera; E G MacEwen; S A Soergel
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.